As one of India's leading pharmaceutical companies incorporated in 1959, Torrent is focused on producing high-quality, affordable medicines for a wide range of diseases. The company demonstrated strong financial momentum in 2024, with revenue reaching ₹115.16 billion (up 7.35% year-over-year) and earnings of ₹19.11 billion (up 15.39%).
Cyborg Score Rationale
Torrent demonstrated double-digit earnings growth in 2024 with 7.35% revenue growth and 15.39% earnings growth. Analyst consensus from Citi maintains a Buy rating with a 20.7% upside target. The company benefits from strong geographic diversification and therapeutic portfolio depth, positioning it well in the growing Indian pharmaceutical market.
Top Insights
Strong 2024 financial performance with 7.35% revenue growth and 15.39% earnings growth demonstrates pricing power and operational efficiency.
Recent FDA Establishment Inspection Report (EIR) for Pithampur facility strengthens US market expansion credentials.
Strategic acquisition plan for up to 2.41% equity stake in JB Chemicals & Pharmaceuticals demonstrates consolidation strategy in competitive market.
Multiple analyst upgrades with Citi targeting ₹4,380 (20.7% upside) indicates institutional confidence in growth trajectory.
Named Competitors
Sun Pharma — India's largest pharma by revenue with global presence
Cipla — Leading Indian pharma with respiratory and infectious disease focus
Lupin — Indian pharma with cardiovascular and CNS specialization
Dr. Reddy's — Vertically integrated pharma player with generics strength
Recent Developments
(February 2026) Stock trading at ₹4,078 with analyst target prices ranging ₹3,530-4,500
(September 2025) Q2 FY26 revenue ₹3,246 Cr with net profit ₹591 Cr showing consistent quarterly growth